It's still an expense though, so I disagree. NPAT is incredibly important IMHO and more important than EBIT.
Horses for courses, but NPAT is still the real bottom line for me.
So NPAT "linear" at best, but it was still negative IMO.
There is also competitor snapping at heels which is in FDA process. Disc Medicine, BEACON. Look it up.
- Forums
- ASX - By Stock
- CUV
- Ann: Appendix 4E and Annual Report 2022
Ann: Appendix 4E and Annual Report 2022, page-7
-
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CUV (ASX) to my watchlist
(20min delay)
|
|||||
Last
$15.25 |
Change
-0.010(0.07%) |
Mkt cap ! $764.0M |
Open | High | Low | Value | Volume |
$15.25 | $15.32 | $15.22 | $415.5K | 27.24K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 459 | $15.22 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.30 | 630 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 459 | 15.220 |
1 | 167 | 15.200 |
1 | 167 | 15.180 |
1 | 167 | 15.160 |
1 | 167 | 15.140 |
Price($) | Vol. | No. |
---|---|---|
15.300 | 630 | 1 |
15.320 | 217 | 2 |
15.340 | 167 | 1 |
15.360 | 167 | 1 |
15.380 | 167 | 1 |
Last trade - 16.10pm 03/07/2024 (20 minute delay) ? |
Featured News
CUV (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, CEO
James Graham
CEO
Previous Video
Next Video
SPONSORED BY The Market Online